Trial Profile
A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Trastuzumab (SB3, EU Sourced Herceptin and US Sourced Herceptin) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2019
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Pharmacokinetics
- Sponsors Samsung Bioepis
- 28 Jun 2016 Results published in the Clinical Therapeutics
- 19 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Mar 2014 New trial record